Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 57 of 95, showing 5 Applications out of 474 total, starting on record 281, ending on 285

# Protocol No Study Title Investigator(s) & Site(s)

281.

ECCT/19/01/02   Opt4Kids
    Optimizing viral load suppression in Kenyan children on antiretroviral therapy (Opt4Kids)   
Principal Investigator(s)
1. Lisa Dillabaugh Abuogi
2. Patrick Oyaro Owiti
Site(s) in Kenya
1. Kisumu County Hospital (Kisumu county)
2. Ahero County Hospital (Kisumu county)
3. Nyakach County Hospital (Kisumu county)
4. Lumumba sub-County Hospital (Kisumu county)
5. Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county)
 
View

282.

ECCT/19/01/01   A Randomized, Open, Parallel-group, Single Dose, Phase 2a Study, to Investigate the Clinical and Parasiticidal Activity and the Pharmacokinetics of 3 dose levels of Artefenomel in combination with Ferroquine (FQ) and FQ alone, in African Patients with Unc
    A Randomized, Open label, Parallel-group, Single Dose Regimen, Phase 2a Study, to Investigate the Clinical and Parasiticidal Activity and the Pharmacokinetics of 3 dose levels of Artefenomel (OZ439) given in combination with Ferroquine (FQ) and FQ alone, in African Patients with Uncomplicated Plasmodium falciparum Malaria   
Principal Investigator(s)
1. Bernhards Ogutu Ragama
Site(s) in Kenya
1. Ahero County hospital (Kisumu county)
2. Siaya County Hospital (Siaya county)
 
View

283.

ECCT/18/12/02   Randomized Controlled Trial to Compare the Effect of Corn-Soy Blend + Vegetable Oil 8 and Fish Oil (CSB-VO-FO) With Corn-Soy Blend + Vegetable Oil Alone (CSB-VO) on 9 the Immunological and Microbiota Patterns among Children Aged 6 to 24 months with 10 Mod
    Randomized Controlled Trial to Compare the Effect of Corn-Soy Blend + Vegetable Oil 8 and Fish Oil (CSB-VO-FO) With Corn-Soy Blend + Vegetable Oil Alone (CSB-VO) on 9 the Immunological and Microbiota Patterns among Children Aged 6 to 24 months with 10 Mod   
Principal Investigator(s)
1. CHRISTOPHER L. MELBY MELBY
Site(s) in Kenya
KENYA MEDICAL RESEARCH INSTITUTE
 
View

284.

ECCT/18/12/01   study to determine if a new malaria vaccine is safe and induces immunity among Kenyan adults, young children and infants.
    A Phase 1b, open-label, age de-escalation, dose-escalation study to evaluate the safety and immunogenicity of different doses of a candidate malaria vaccine; adjuvanted R21(R21/MM) in adults, young children and infants in Kilifi, Kenya.   
Principal Investigator(s)
1. Mainga Hamaluba
Site(s) in Kenya
KEMRI-Wellcome Trust Research Programme (KWTRP) Centre for Geographic Medical Research - Coast (CGMRC), Kilifi, Kenya.
 
View

285.

ECCT/18/11/02   EPI 003
    A prospective study to evaluate the safety, effectiveness and impact of the RTS,S/AS01E vaccine in young children in sub-Saharan Africa.   
Principal Investigator(s)
1. BERNHARDS OGUTU
Site(s) in Kenya
1. • Ahero Clinical Trials Unit (Kisumu county)
2. KEMRI Walter Reed Army Institute of Research (Kisumu county)
3. KEMRI CDC SIAYA (Siaya county)
 
View